10 results
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
10 Aug 23
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
7:19am
of investigational MGD-based medicines and the discovery of additional MGD development candidates through our innovative QuEEN™ discovery engine."
In addition
10-K
2021 FY
GLUE
Monte Rosa Therapeutics Inc
29 Mar 22
Annual report
4:15pm
development tools, to our growing library of MGDs, and to the innovative methods and approaches we have developed to rationally design MGDs and to expand our … as the original innovative drug or for another indication. However, such an application may be submitted after four years if it contains a certification
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
29 Mar 22
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
7:41am
of the collaboration is to leverage innovative covalent chemistry to further expand the target space for molecular glue degradation
Strengthened executive leadership
424B4
GLUE
Monte Rosa Therapeutics Inc
25 Jun 21
Prospectus supplement with pricing info
6:08am
the drug is intended for the same indication as the original innovative drug or for another indication. However, such an application may be submitted … perform an accelerated review of a MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need
S-1/A
l0frsv73fpsw
9 Jun 21
IPO registration (amended)
4:51pm
S-1
6ryxlld9t8e
4 Jun 21
IPO registration
9:07am
DRS/A
7p6mbh 32bes6584u
21 May 21
Draft registration statement (amended)
12:00am
DRS
mfun phuyo2g50whqfo0
19 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next